Difference between revisions of "Mitotane (Lysodren)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Adrenocortical carcinoma]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 23: | Line 23: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category: | + | [[Category:Adrenocortical carcinoma medications]] |
[[Category:Drugs FDA approved in 1970]] | [[Category:Drugs FDA approved in 1970]] | ||
Revision as of 01:12, 28 January 2018
General information
Class/mechanism: Adrenal cytotoxic agent, suppresses adrenal cortex and the extra-adrenal metabolism of cortisol.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
Also known as
- Generic name: o,p′-DDD
- Brand name: Lysodren